Drugs / Fusilev
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FUSILEV | — | 2011-04-29 | fda.gov ↗ |
| Approved | US (FDA) | FUSILEV | — | 2008-03-07 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01820091 | Apr 2013 → Apr 2015 | non-small cell lung carcinoma | Acrotech Biopharma Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT01789723 | Mar 2013 → Mar 2015 | non-Hodgkin lymphoma | Acrotech Biopharma Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fusilev | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01820091 ↗ |
| Known as | Fusilev - (Levoleucovorin) | “Fusilev - (Levoleucovorin)” NCT01789723 ↗ |
| Route | Intravenous | “Fusilev will be administered by IV push (3-5 minutes)” NCT01789723 ↗ |